Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib, Toripalimab, and Nab-paclitaxel in Advanced Pancreatic Cancer
NCT04718701Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2021
- Primary completion
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and toripalimab in pancreatic cancer (PC), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Progression-free survival at 24 months. Status: unknown.
02
Drugs
anlotinibtoripalimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04718701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04718701.